Ocrevus access in Sri Lanka: the NMRA named-patient pathway
How patients in the Democratic Socialist Republic of Sri Lanka legally obtain Ocrevus (ocrelizumab) when the locally registered indication, stocked presentation, or payer coverage does not match what the prescribing physician has written.
Last reviewed 2026-05-12 by Reserve Meds clinical and regulatory team.
Quick orientation
Patients in Sri Lanka access Ocrevus (ocrelizumab) for relapsing and primary progressive multiple sclerosis through the NMRA named-patient pathway, a the National Medicines Regulatory Authority-administered mechanism that allows a Sri Lankan-licensed physician at a registered facility to import the FDA-labelled product for a specific named patient. This page details the documentation, approval timeline, and real cost in LKR.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Reserved for you.
Why Sri Lankan patients need Ocrevus through the named-patient pathway
The Democratic Socialist Republic of Sri Lanka operates a structured pharmaceutical regulatory environment. Ocrevus (ocrelizumab) is regulated through NMRA (the National Medicines Regulatory Authority) channels, and a Sri Lankan family asking for Ocrevus is rarely asking for a medicine that does not exist locally. They are usually asking for a precise version of it that the local market has not caught up to.
Four converging patterns drive these cases. First, indication lag. Ocrevus's newer FDA-approved indications and dosing expansions often reach local registration 12 to 36 months after the US label. A family whose treating physician has documented a clear FDA-label fit may still find that the local label has not caught up. Second, presentation gaps. The exact strength, weight-banded dose, or pen format the prescriber needs may not be stocked at the local agent even when the medicine is registered. Third, payer denial. out-of-pocket cash with Ceylinco Healthcare, Sri Lanka Insurance Corporation, AIA Lanka, and Allianz Lanka private plans each assess specialty therapies case by case, and step-therapy or formulary rules often produce denials even when the drug is on the local register. Cash-pay families pursue cross-border supply rather than wait through appeals. Fourth, continuity of supply. When a US-stable patient relocates to Sri Lanka or visits family for an extended period, maintaining the original FDA-sourced regimen matters more than switching to a different local presentation.
In each pattern, the NMRA named-patient pathway is the mechanism that connects a Sri Lankan-licensed physician's clinical decision with US-sourced, FDA-labeled product for a specific patient. Clinically, Ocrevus is a humanised anti-CD20 monoclonal antibody that depletes CD20-positive B lymphocytes implicated in MS pathophysiology, and the named-patient route preserves that mechanism rather than substituting a non-equivalent local option.
The NMRA named-patient pathway for Ocrevus
The pathway for a Sri Lankan-licensed physician to obtain a medicine that is not registered or not stocked locally is the Waiver of Registration (WoR) named-patient import authorisation administered by the National Medicines Regulatory Authority (NMRA) under the National Medicines Regulatory Authority Act No. 5 of 2015, which allows a treating consultant at a registered facility to apply for the import of an unregistered medicine for a specific named patient where the medicine is approved by a recognised reference authority and no clinically equivalent locally registered option is suitable. The framework allows registered healthcare facilities to import a specific medicine for a specific patient when the medicine is approved by a recognised reference authority (typically the US FDA, EMA, MHRA, PMDA Japan, or Health Canada) and a clinically equivalent locally registered alternative is not suitable. For Ocrevus specifically, the clinical justification typically frames the case around the precise FDA-approved indication and the documented gap in the local route.
A complete application includes a clinical justification letter from the treating physician (diagnosis, severity, prior therapies, why this specific drug, why the locally stocked option is not suitable for this case), the treating physician's Sri Lankan medical license verification through the Sri Lanka Medical Council (SLMC) and the NMRA, an anonymised patient identifier where the NMRA submission allows, full product details (brand name, generic name, manufacturer, strength, dosage form, pack size, quantity requested, intended treatment duration), the destination dispensing facility name, license number, and pharmacy in charge, and a chain-of-custody plan describing how the medicine will move from the US manufacturer through the importer to the dispensing pharmacy.
For Ocrevus, the clinical justification angle typically rests on one or more of three documented elements: a pediatric or weight-banded request that fits the FDA label but not the local label, a denied biologic or specialty claim where prior step-therapy has been documented, or a continuity-of-supply request for a patient previously stabilised on the US-sourced presentation. The treating physician documents the relevant clinical criteria for the prescribed indication: severity scores, biomarker levels, prior therapy failures, and the rationale for Ocrevus versus the next-in-line local alternative.
Approval timelines for routine cases are typically 14 to 30 business days. Complex cases (rare indication, larger quantities, first import of a given pediatric or weight-banded format) can extend to 8 to 12 weeks. NMRA retains discretion on timing, and we do not promise specific durations.
Where Ocrevus gets dispensed in Sri Lanka
A small group of Sri Lankan institutions handle named-patient imports as established workflow, with in-house import pharmacy infrastructure and physicians experienced with the application set. Tertiary and major private hospitals that meet this profile include Asiri Central Hospital in Colombo, Lanka Hospitals (formerly Apollo Hospitals Colombo), and Nawaloka Hospitals in Colombo. Each maintains pharmacy infrastructure appropriate to the storage requirements of the imported medicine (2 to 8 degrees Celsius cold-chain for biologics, ambient storage for oral therapies, ultra-cold or specialised handling where the FDA label requires it).
For physicians at smaller hospitals without internal import infrastructure, the common pattern is to route through a specialty importer that holds a pharmaceutical establishment license and files the NMRA application on the prescribing physician's behalf. The medicine then moves into the prescribing hospital's outpatient or specialty pharmacy under chain-of-custody documentation.
Real cost picture for Ocrevus in Sri Lanka
US WAC for Ocrevus runs in the range of USD 64,400 to USD 75,600 per year at the standard FDA-labelled regimen for relapsing and primary progressive multiple sclerosis. LKR is trading at approximately 300 LKR to 1 USD, so the annual reference range converts to roughly LKR 19,320,000 to LKR 22,680,000 for the drug itself at US WAC equivalents.
International logistics for shipment to Sri Lanka typically runs USD 350 to USD 1200 depending on destination city, urgency, and presentation (cold-chain biologics carry the higher end of the range; ambient oral solids the lower). The Democratic Socialist Republic of Sri Lanka customs and NMRA permit fees are nominal relative to drug cost. Reserve Meds' concierge fee is itemised separately on every firm quote.
On the insurance side, out-of-pocket cash with Ceylinco Healthcare, Sri Lanka Insurance Corporation, AIA Lanka, and Allianz Lanka private plans each assess named-patient imports case by case. Some reimburse fully when the medicine is on their formulary even if not stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We do not promise coverage from any insurer. US manufacturer copay cards and patient assistance programs do not extend internationally; cross-border patients pay cash or rely on local payer coverage.
Typical timeline for Ocrevus in Sri Lanka
NMRA routine processing is typically 14 to 30 business days from a complete filing. International logistics adds 2 to 5 additional days depending on whether the presentation is ambient or cold-chain, the dispensing city, and customs clearance. End-to-end, most routine adult cases complete within 3 to 6 weeks from first complete documentation. Pediatric, weight-banded, or first-import cases can run slightly longer because presentation selection and first-import scrutiny can extend NMRA review.
For temperature-sensitive products, the dispensing facility must maintain validated storage with continuous monitoring; the manufacturer's room-temperature excursion runway on the FDA label informs how we plan the Gulf, South Asia, or North Africa shipping lane, and the cold chain is broken only at the dispensing pharmacy under documented control.
When a case is on a clinical clock (a flare, a new diagnosis with an active disease, or a treatment cycle scheduled at the dispensing centre), the practical question is which step controls the timeline. In our experience the binding step is rarely the NMRA review itself when the application is filed clean; it is usually documentation completeness on the prescriber's side or, for cold-chain biologics, the dispensing facility's storage and monitoring confirmation. The intake is where we lock the case-team contact, gather the documents in parallel, and start the US sourcing clock so that approval and product land in the same week rather than serially.
What your physician needs to provide
For a Sri Lankan-licensed specialist prescribing Ocrevus through the NMRA pathway, the clinical justification letter is the cornerstone of the application. The letter typically documents the patient's confirmed diagnosis for relapsing and primary progressive multiple sclerosis, severity assessment (scoring instrument, biomarker, imaging, or biopsy as appropriate for the indication), prior therapy history including first-line options tried, and a clinical rationale for why Ocrevus is the appropriate next step given a humanised anti-CD20 monoclonal antibody that depletes CD20-positive B lymphocytes implicated in MS pathophysiology.
The letter also specifies the exact dosing plan per the FDA-approved label: starting dose, maintenance dose, route of administration, schedule, and intended duration of therapy. Monitoring plan should reference any baseline laboratory or imaging requirements specific to Ocrevus (full blood count, liver function, infection screen, ophthalmology assessment, or pregnancy testing where the FDA label requires it), planned follow-up intervals, and dose-modification criteria for the most common adverse events.
The treating physician's Sri Lankan license number, the dispensing facility license number, and the pharmacy in charge of dispensing complete the package. For cold-chain or specialty-handling products, the dispensing pharmacy's documented storage protocol and continuous-temperature-monitoring log are part of the chain-of-custody record we share with the importer.
What to monitor on Ocrevus
Ocrevus sits in the anti-CD20 class with Briumvi (ublituximab) and Kesimpta (ofatumumab). Four safety signals stand out for the patient and the treating neurology team: hepatitis B reactivation, progressive multifocal leukoencephalopathy (PML) and JC virus, persistent hypogammaglobulinaemia, and infusion reactions. Each is described below with the monitoring cadence and the prescribing-information citation.
Hepatitis B reactivation. Pre-treatment screening for hepatitis B is mandatory before the first Ocrevus dose: HBsAg and anti-HBc (total) at minimum, with anti-HBs added where available (Ocrevus Prescribing Information, section 5.2). Patients with chronic hepatitis B require hepatology co-management and antiviral prophylaxis before B-cell depletion. Patients with resolved hepatitis B (HBsAg negative, anti-HBc positive) need a frank discussion of reactivation risk and a monitoring plan; many centres add periodic HBV DNA testing during therapy. Reference: Ocrevus (ocrelizumab) Prescribing Information, Genentech (Roche), section 5.2.
Progressive multifocal leukoencephalopathy (PML) and JC virus. Anti-CD20 therapies including ocrelizumab carry a class risk for PML, a rare and serious brain infection caused by reactivation of the JC virus in immunosuppressed patients. Symptoms include progressive limb weakness, behavioural and cognitive changes, and disturbance of vision or speech. PML cases on ocrelizumab have been reported in the post-marketing setting, including patients with no prior natalizumab exposure (Ocrevus Prescribing Information, section 5.4). Baseline JC virus antibody serology is not mandated by the FDA label, but most MS neurology programmes order it for risk stratification, particularly when sequencing onto Ocrevus from natalizumab (Tysabri). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Reference: Ocrevus Prescribing Information, section 5.4, US FDA approval March 2017.
Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Ocrevus label requires baseline measurement of serum immunoglobulins (IgG, IgA, IgM) before treatment initiation, with monitoring during treatment and after discontinuation until B-cell repletion (Ocrevus Prescribing Information, section 5.7). MS-experienced centres typically check quantitative immunoglobulins at baseline and every six months at the maintenance-infusion visit. Persistent hypogammaglobulinaemia, in particular IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Ocrevus Prescribing Information, section 5.7; Hauser SL et al., Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis (OPERA I and II), N Engl J Med 2017;376(3):221-234.
Infusion reactions and premedication. Infusion reactions are among the most frequent adverse events in the OPERA I and II and ORATORIO trials, occurring in approximately 34 percent of Ocrevus-treated patients and most often with the first (Day 1, 300 mg) infusion. Premedication is mandatory before each infusion: methylprednisolone 100 mg IV (or equivalent corticosteroid) approximately 30 minutes pre-infusion, plus an oral or IV antihistamine such as diphenhydramine 25 to 50 mg, plus an antipyretic such as paracetamol 650 mg orally (Ocrevus Prescribing Information, section 2 dosing and administration, and section 5.1). The first dose is split into two 300 mg infusions two weeks apart, each delivered over approximately 2.5 hours with continuous observation; maintenance 600 mg infusions run over approximately 3.5 hours, or 2 hours with the shorter-infusion protocol in eligible patients. Reactions may present as throat tightness, flushing, headache, fever, urticaria, bronchospasm, or hypotension and are managed by slowing or temporarily stopping the infusion, optimising premedication, and observing recovery before resuming. Severe reactions, including anaphylaxis, require permanent discontinuation. References: Ocrevus Prescribing Information, section 5.1 and section 2; Montalban X et al., Ocrelizumab versus placebo in primary progressive multiple sclerosis (ORATORIO), N Engl J Med 2017;376(3):209-220.
Common questions about Ocrevus in Sri Lanka
Will out-of-pocket cash with Ceylinco Healthcare, Sri Lanka Insurance Corporation, AIA Lanka, and Allianz Lanka private plans cover this? Each insurer assesses named-patient imports case by case. Some reimburse fully when Ocrevus is on their formulary even if not currently stocked, some reimburse a percentage subject to copay, and many require pre-authorisation. We supply the documentation set that allows your insurer to assess the case; the claim itself sits with you or your hospital.
Is the FDA-approved indication recognised by NMRA? The NMRA named-patient pathway exists precisely to permit access when the local registration or stocking lags the FDA label. The application documents the FDA indication, the reference-authority approval, and the local gap; NMRA review focuses on the clinical justification rather than re-litigating the FDA decision.
My physician is licensed in one emirate / state / province and the hospital is in another. Is that fine? Any Sri Lankan-licensed physician practicing in good standing in the jurisdiction of the dispensing facility has signing authority on the clinical justification letter. The Sri Lanka Medical Council (SLMC) and the NMRA verifies the active license; the NMRA application records both the prescribing physician and the dispensing facility.
Can I receive Ocrevus at home? The dispensing facility must be Sri Lankan-licensed. The hospital outpatient or specialty pharmacy releases the medicine to you after final verification, and you then administer or self-administer at home where the FDA label permits, after the dispensing pharmacy's training. The cold-chain or controlled-storage handoff ends at the dispensing pharmacy; home storage and any handling protocol are part of your patient onboarding kit.
What about competitors or alternative therapies in the same class? Choice of therapy depends on the patient's full phenotype, prior therapy, and the prescriber's judgment. Reserve Meds coordinates whichever medicine the physician has prescribed; we do not substitute, advise on substitution, or promote one brand over another.
Where Reserve Meds fits in Ocrevus cases
Reserve Meds is a US-based concierge coordinator. We do not replace your treating physician, we do not replace NMRA, and we do not replace your dispensing pharmacy. For Ocrevus specifically, we orchestrate the US-side sourcing through a DSCSA-compliant specialty channel, build the documentation packet your physician submits, coordinate validated logistics (cold-chain with continuous temperature logging where the FDA label requires it) into Sri Lanka, and assign a single named coordinator through the case. Standard named-patient coordination under our specialty playbook applies. Presentation selection, dose-band confirmation, and patient onboarding for self-administration where applicable are the recurring operational fundamentals we expect for this drug.
Operationally, a typical Ocrevus case runs across four parallel tracks. The clinical track is the physician's: justification letter, dosing plan, monitoring schedule, and the next patient-facing follow-up. The regulatory track is the NMRA application packaged by the importer; we provide the documentation template, the dispensing facility license check, and the chain-of-custody attestation. The logistics track is the US-side sourcing and the validated international shipment with continuous temperature logging and customs broker coordination. The patient-experience track is the named coordinator who keeps everyone aligned on dates, addresses dispensing-pharmacy questions, and confirms the medicine has been received and stored correctly. The four tracks are run in parallel rather than in series; that is the operational difference between a 3-week and a 9-week case.
Sri Lankan tertiary specialty care concentrates at Asiri Central, Lanka Hospitals, and Nawaloka in Colombo, with the National Cancer Institute Maharagama serving as the principal oncology referral site; the NMRA Waiver of Registration pathway is the standard mechanism for unregistered specialty medicines.
Next step
If your Sri Lankan physician has prescribed Ocrevus and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.